ResMed Inc. (NYSE:RMD) is one of the most undervalued large cap stocks to buy according to analysts. On June 1, ResMed finalized its acquisition of Noctrix Health, a medical device company known for developing non-pharmacologic wearable therapeutics. This strategic move expands ResMed’s clinical sleep health portfolio into the treatment of Restless Legs Syndrome/RLS, which is the third most prevalent sleep disorder globally.
The centerpiece of the acquisition is the Nidra Tonic Motor Activation/TOMAC Therapy. This FDA De Novo classified, non-invasive device is specifically designed to reduce symptoms in adults with moderate-to-severe RLS who have not achieved sufficient relief through traditional drug therapies. The technology is backed by robust clinical validation, including inclusion in American Academy of Sleep Medicine/AASM guidelines.
ResMed Inc. (NYSE:RMD) plans to integrate this technology into its existing ecosystem of connected devices and digital health solutions to improve patient access and care pathways. Following the completion of the deal, Noctrix Health now operates as a wholly owned subsidiary of ResMed, supporting the company’s broader 2030 strategy to advance home-based sleep and respiratory care
Copyright: djoronimo / 123RF Stock Photo
ResMed Inc. (NYSE:RMD) develops and manufactures medical devices and digital health solutions for sleep apnea, chronic obstructive pulmonary disease, and other respiratory conditions. Its products include CPAP machines, masks, and cloud-connected software platforms that enable remote patient monitoring and management
While we acknowledge the potential of RMD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock
READ NEXT: 33 Stocks That Should Double in 3 YearsandCathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News
